Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity.
T-cell bispecific antibody
carcinoembryonic antigen T-cell bispecific antibody
combination
humanized mice
immunotherapy
programmed death–ligand 1
solid tumors
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
24
06
2020
accepted:
29
10
2020
entrez:
17
12
2020
pubmed:
18
12
2020
medline:
18
12
2020
Statut:
epublish
Résumé
T-cell Bispecific Antibodies (TCBs) elicit anti-tumor responses by cross-linking T-cells to tumor cells and mediate polyclonal T-cell expansion that is independent of T-cell receptor specificity. TCBs thus offer great promise for patients who lack antigen-specific T-cells or have non-inflamed tumors, which are parameters known to limit the response of checkpoint inhibitors. The current study deepens the understanding of TCB mode of action and elaborates on one of the adaptive resistance mechanisms following its treatment
Identifiants
pubmed: 33330050
doi: 10.3389/fonc.2020.575737
pmc: PMC7735156
doi:
Types de publication
Journal Article
Langues
eng
Pagination
575737Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2020 Sam, Colombetti, Fauti, Roller, Biehl, Fahrni, Nicolini, Perro, Nayak, Bommer, Schoenle, Karagianni, Le Clech, Steinhoff, Klein, Umaña and Bacac.
Déclaration de conflit d'intérêts
The authors declare that this study received funding from F Hoffmann-La Roche Ltd. The funder had the following involvement with the study: study design, generation of the molecules tested in the study, data collection and analysis, decision to publish, and editorial support for the preparation of this manuscript. All authors are employees of F Hoffmann-La Roche Ltd.
Références
Clin Cancer Res. 2016 Apr 15;22(8):1865-74
pubmed: 27084740
Cancer Res. 1994 Aug 1;54(15):4169-76
pubmed: 8033149
Mol Cancer Ther. 2012 May;11(5):1062-70
pubmed: 22532596
Cancer Immunol Immunother. 2015 Jun;64(6):677-88
pubmed: 25742933
Sci Transl Med. 2019 Jun 12;11(496):
pubmed: 31189721
Cell. 2017 Sep 7;170(6):1109-1119.e10
pubmed: 28886381
Sci Transl Med. 2018 Oct 3;10(461):
pubmed: 30282693
Science. 2018 Mar 23;359(6382):1350-1355
pubmed: 29567705
Nat Biotechnol. 2013 Nov;31(11):999-1008
pubmed: 24142051
Leukemia. 2016 Feb;30(2):484-91
pubmed: 26239198
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
Radiology. 2013 Apr;267(1):173-82
pubmed: 23329660
Clin Cancer Res. 2016 Apr 15;22(8):1845-55
pubmed: 27084738
Nat Commun. 2018 Jan 2;9(1):32
pubmed: 29296022
Clin Cancer Res. 2015 Sep 15;21(18):4035-9
pubmed: 26374073
Front Oncol. 2018 Jul 25;8:285
pubmed: 30090763
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Cancer Res. 2017 Oct 1;77(19):5384-5394
pubmed: 28819027
Immunity. 2020 Jan 14;52(1):17-35
pubmed: 31940268
Eur J Cancer. 2017 Aug;81:116-129
pubmed: 28623775
Cancer Discov. 2015 Sep;5(9):915-9
pubmed: 26272491
Oncoimmunology. 2017 Mar 10;6(3):e1267891
pubmed: 28405494
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
Cancer Treat Rev. 2018 Feb;63:40-47
pubmed: 29207310
Cancer J. 2018 Jan/Feb;24(1):47-53
pubmed: 29360728
Nat Rev Clin Oncol. 2020 Jul;17(7):418-434
pubmed: 32242094
Int J Cancer. 2000 Jun 15;86(6):863-9
pubmed: 10842202
Annu Rev Med. 2019 Jan 27;70:437-450
pubmed: 30379598
Int J Cancer. 1991 Apr 22;48(1):85-91
pubmed: 2019461
Nat Rev Drug Discov. 2018 Feb 1;17(2):86
pubmed: 29386608
Nat Commun. 2017 Feb 21;8:14572
pubmed: 28220772
Pharmacol Ther. 2018 Feb;182:161-175
pubmed: 28834699
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Clin Cancer Res. 2016 Jul 1;22(13):3286-97
pubmed: 26861458
Sci Transl Med. 2019 Sep 4;11(508):
pubmed: 31484792
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Nat Methods. 2012 Mar 04;9(4):357-9
pubmed: 22388286
Pharmacol Ther. 2019 Sep;201:103-119
pubmed: 31028837
Cancer Res. 2014 Oct 1;74(19):5561-71
pubmed: 25228655
J Nucl Med. 1990 Apr;31(4):473-9
pubmed: 2324823
Cancer Treat Rev. 2010 Oct;36(6):458-67
pubmed: 20347527
Cancer Res. 1998 Apr 1;58(7):1469-77
pubmed: 9537250
Science. 2020 May 29;368(6494):930-933
pubmed: 32467373
Cancer Immunol Res. 2016 Jul;4(7):563-8
pubmed: 27197067
Cancer Cell. 2017 Mar 13;31(3):396-410
pubmed: 28262554
Antibodies (Basel). 2019 Jul 03;8(3):
pubmed: 31544847
Oncoimmunology. 2015 Jun 24;5(2):e1062969
pubmed: 27057429
Clin Cancer Res. 2018 Oct 1;24(19):4785-4797
pubmed: 29716920
Clin Cancer Res. 2020 May 1;26(9):2188-2202
pubmed: 31996389
Nature. 2015 Jul 9;523(7559):231-5
pubmed: 25970248
J Immunol. 2002 Apr 1;168(7):3195-204
pubmed: 11907072
Nat Rev Clin Oncol. 2010 Mar;7(3):153-62
pubmed: 20142816